HSBC downgrades Illumina on China risks, funding concerns
HSBC noted that Illumina is losing its market dominance, with declining instrument placements in the low-to-mid throughput ...
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or ...
Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an ...
Investing1 天
Roche Holding AG (RO)
Investing.com -- Roche (SIX:RO) on Thursday said it expects high single-digit growth in core profit for 2025, following a strong performance in 2024 driven by strong sales in both ...
英为财情1 天
罗氏控股公司ADR (RHHBY)
罗氏控股ADR (RHHBY) (ISIN: US7711951043)股票专题，提供今日罗氏控股ADR(RHHBY) (ISIN: US7711951043)股票最新股价查询，实时市场行情，走势图表，及罗氏控股公司ADR(RHHBY) (ISIN: US7711951043)股票的专业技术分析，投资者论坛，历史交易数据，最新消息和未来价格预测。 罗氏 ...
Berenberg Bank Sticks to Their Hold Rating for Roche Holding AG (RHHVF)
In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a ...
Roche: Sustainable Sales Growth, Margin Leverage, And Supportive Late-Stage Pipeline
Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...
Merck's Oncology Strength: Beating Wall Street Again
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
J.P. Morgan Keeps Their Sell Rating on Roche Holding AG (RHHVF)
J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...